Literature DB >> 28406343

Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.

Thomas Botzanowski1, Stéphane Erb1, Oscar Hernandez-Alba1, Anthony Ehkirch1, Olivier Colas2, Elsa Wagner-Rousset2, David Rabuka3, Alain Beck2, Penelope M Drake3, Sarah Cianférani1.   

Abstract

Antibody-drug conjugates (ADCs) have emerged as a family of compounds with promise as efficient immunotherapies. First-generation ADCs were generated mostly via reactions on either lysine side-chain amines or cysteine thiol groups after reduction of the interchain disulfide bonds, resulting in heterogeneous populations with a variable number of drug loads per antibody. To control the position and the number of drug loads, new conjugation strategies aiming at the generation of more homogeneous site-specific conjugates have been developed. We report here the first multi-level characterization of a site-specific ADC by state-of-the-art mass spectrometry (MS) methods, including native MS and its hyphenation to ion mobility (IM-MS). We demonstrate the versatility of native MS methodologies for site-specific ADC analysis, with the unique ability to provide several critical quality attributes within one single run, along with a direct snapshot of ADC homogeneity/heterogeneity without extensive data interpretation. The capabilities of native IM-MS to directly access site-specific ADC conformational information are also highlighted. Finally, the potential of these techniques for assessing an ADC's heterogeneity/homogeneity is illustrated by comparing the analytical characterization of a site-specific DAR4 ADC to that of first-generation ADCs. Altogether, our results highlight the compatibility, versatility, and benefits of native MS approaches for the analytical characterization of all types of ADCs, including site-specific conjugates. Thus, we envision integrating native MS and IM-MS approaches, even in their latest state-of-the-art forms, into workflows that benchmark bioconjugation strategies.

Entities:  

Keywords:  Antibody-drug conjugate (ADC); ion mobility-mass spectrometry (IM-MS); middle level; native mass spectrometry; site-specific bioconjugation; top level

Mesh:

Substances:

Year:  2017        PMID: 28406343      PMCID: PMC5524152          DOI: 10.1080/19420862.2017.1316914

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  CIUSuite: A Quantitative Analysis Package for Collision Induced Unfolding Measurements of Gas-Phase Protein Ions.

Authors:  Joseph D Eschweiler; Jessica N Rabuck-Gibbons; Yuwei Tian; Brandon T Ruotolo
Journal:  Anal Chem       Date:  2015-10-30       Impact factor: 6.986

3.  Ion mobility-mass spectrometry analysis of large protein complexes.

Authors:  Brandon T Ruotolo; Justin L P Benesch; Alan M Sandercock; Suk-Joon Hyung; Carol V Robinson
Journal:  Nat Protoc       Date:  2008-06-19       Impact factor: 13.491

4.  Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates.

Authors:  Santiago E Farias; Pavel Strop; Kathy Delaria; Meritxell Galindo Casas; Magdalena Dorywalska; David L Shelton; Jaume Pons; Arvind Rajpal
Journal:  Bioconjug Chem       Date:  2014-01-08       Impact factor: 4.774

5.  Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.

Authors:  Patrick Dennler; Aristeidis Chiotellis; Eliane Fischer; Delphine Brégeon; Christian Belmant; Laurent Gauthier; Florence Lhospice; François Romagne; Roger Schibli
Journal:  Bioconjug Chem       Date:  2014-02-12       Impact factor: 4.774

Review 6.  Mechanisms of Resistance to Antibody-Drug Conjugates.

Authors:  Frank Loganzo; Matthew Sung; Hans-Peter Gerber
Journal:  Mol Cancer Ther       Date:  2016-10-25       Impact factor: 6.261

7.  MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation.

Authors:  Oleksandr Koniev; Sergii Kolodych; Zoljargal Baatarkhuu; Johann Stojko; Jitka Eberova; Jean-Yves Bonnefoy; Sarah Cianférani; Alain Van Dorsselaer; Alain Wagner
Journal:  Bioconjug Chem       Date:  2015-09-03       Impact factor: 4.774

8.  Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II).

Authors:  Dona York; Jeanne Baker; Patrick G Holder; Lesley C Jones; Penelope M Drake; Robyn M Barfield; Gregory T Bleck; David Rabuka
Journal:  BMC Biotechnol       Date:  2016-02-24       Impact factor: 2.563

9.  Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.

Authors:  Alain Beck; John Lambert; Michael Sun; Kedan Lin
Journal:  MAbs       Date:  2012-08-22       Impact factor: 5.857

10.  Chemoenzymatic Fc glycosylation via engineered aldehyde tags.

Authors:  Elizabeth L Smith; John P Giddens; Anthony T Iavarone; Kamil Godula; Lai-Xi Wang; Carolyn R Bertozzi
Journal:  Bioconjug Chem       Date:  2014-04-07       Impact factor: 4.774

View more
  17 in total

1.  A Case Study to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate Using Middle-Down Mass Spectrometry.

Authors:  Oscar Hernandez-Alba; Stéphane Houel; Steve Hessmann; Stéphane Erb; David Rabuka; Romain Huguet; Jonathan Josephs; Alain Beck; Penelope M Drake; Sarah Cianférani
Journal:  J Am Soc Mass Spectrom       Date:  2019-08-19       Impact factor: 3.109

2.  VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH.

Authors:  Lucie Hartmann; Thomas Botzanowski; Mathieu Galibert; Magali Jullian; Eric Chabrol; Gabrielle Zeder-Lutz; Valérie Kugler; Johann Stojko; Jean-Marc Strub; Gilles Ferry; Lukasz Frankiewicz; Karine Puget; Renaud Wagner; Sarah Cianférani; Jean A Boutin
Journal:  Protein Sci       Date:  2019-08-29       Impact factor: 6.725

3.  Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.

Authors:  Yuwei Tian; Jennifer L Lippens; Chawita Netirojjanakul; Iain D G Campuzano; Brandon T Ruotolo
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

Review 4.  Collision induced unfolding of isolated proteins in the gas phase: past, present, and future.

Authors:  Sugyan M Dixit; Daniel A Polasky; Brandon T Ruotolo
Journal:  Curr Opin Chem Biol       Date:  2017-12-05       Impact factor: 8.822

Review 5.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

Review 6.  High-Resolution Native Mass Spectrometry.

Authors:  Sem Tamara; Maurits A den Boer; Albert J R Heck
Journal:  Chem Rev       Date:  2021-08-20       Impact factor: 72.087

7.  Rapid and Simultaneous Characterization of Drug Conjugation in Heavy and Light Chains of a Monoclonal Antibody Revealed by High-Resolution Ion Mobility Separations in SLIM.

Authors:  Gabe Nagy; Isaac K Attah; Christopher R Conant; Weijing Liu; Sandilya V B Garimella; Harsha P Gunawardena; Jared B Shaw; Richard D Smith; Yehia M Ibrahim
Journal:  Anal Chem       Date:  2020-03-17       Impact factor: 6.986

8.  Rapid Analysis of Reduced Antibody Drug Conjugate by Online LC-MS/MS with Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.

Authors:  Eli J Larson; Yanlong Zhu; Zhijie Wu; Bifan Chen; Zhaorui Zhang; Shiyue Zhou; Linjie Han; Qunying Zhang; Ying Ge
Journal:  Anal Chem       Date:  2020-10-27       Impact factor: 8.008

9.  State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.

Authors:  Evolène Deslignière; Anthony Ehkirch; Bastiaan L Duivelshof; Hanna Toftevall; Jonathan Sjögren; Davy Guillarme; Valentina D'Atri; Alain Beck; Oscar Hernandez-Alba; Sarah Cianférani
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

10.  Targeting cancer with antibody-drug conjugates: Promises and challenges.

Authors:  Alexis Q Dean; Shen Luo; Julianne D Twomey; Baolin Zhang
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.